Current recommendations for levothyroxine treatment of differentiated thyroid cancer patients are not properly implemented in clinical practice

Journal of Endocrinological Investigation

Volumn 35, Issue 10, 2012, Pages 901-904

  Martins De Almeida, J F ^a   Goncalves Tsumura W ^a   Vaisman, M ^b   Montalli Assumpcao L V ^a   Ward, L S ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Adequate treatment; Adherence; Collateral effects; Levothyroxine; Tumor control

Indexed keywords

LEVOTHYROXINE; THYROGLOBULIN; THYROTROPIN;

ADULT; ARTICLE; CANCER RECURRENCE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COMORBIDITY; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; THYROTROPIN BLOOD LEVEL;

CELL DIFFERENTIATION; CHOICE BEHAVIOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK FACTORS; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN; THYROXINE; TUMOR MARKERS, BIOLOGICAL;

EID: 84871892819     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8369     Document Type: Article

References (18)

1. Fredlund BO, Olsson SB. Long QT interval and ventricular tachycardia of "torsade de pointe" type in hypothyroidism. Acta Med Scand 1983, 213: 231-5. (Pubitemid 13130098)
2. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001, 344: 501-9. (Pubitemid 32164903)
3. Gogakos AI, Duncan BJH, Williams, GR. Thyroid and bone. Arch Biochem Biophys 2010, 503: 129-36.
4. Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 2010, 20: 135-46.
5. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19: 1167-214.
6. Pitoia F, Ward L, Wohllk N, et al. Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol 2009, 53: 884-7.
7. Lubin E, Mechlis-Frish, Zatz S, et al. Serum thyroglobulin and iodine- 131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. J Nucl Med 1994, 35: 257-62.
8. Brabant G. Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets? J Clin Endocrinol Metab 2008, 93: 1167-9. (Pubitemid 351519702)
9. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006, 16: 1229-42. (Pubitemid 46080167)
10. McGriff NJ, Csako G, Gourgiotis L, Lori C G, Pucino F, Sarlis NJ. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 2002, 34: 554-64. (Pubitemid 36113813)
11. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994, 331: 1249-52. (Pubitemid 24333188)
12. Hovens GC, Stokkel MP, Kievit J, et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 2007, 92: 2610-5. (Pubitemid 47037365)
13. Toft AD. Clinical practice. Subclinical hyperthyroidism. N Engl J Med 2001, 345: 512-6.
14. Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on longterm thyroxine therapy. J Clin Endocrinol Metab 2010, 95: 186-93.
15. Camargo R, Corigliano S, Friguglietti C, et al; Latin American thyroid society. Latin American thyroid society recommendations for the management of thyroid nodules. Arq Bras Endocrinol Metabol 2009, 53: 1167-75.
16. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996, 81: 4318-23. (Pubitemid 26412036)
17. Wang PW, Wang ST, Liu RT, et al. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999, 84: 4549-53.
18. Bagattoli RM, Vaisman M, Lima JS, et al. Estudo de adesão ao tratamento do hipotiroidismo. Arq Bras Endo Metab 2000, 44: 483-7.